.Long-term (Investment) Activity Analysis
Difficulty: Beginner
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Ratios (Summary)
AbbVie Inc., long-term (investment) activity ratios
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| | Net fixed asset turnover | |||||
| | Total asset turnover | |||||
| | Equity turnover |
Source: Based on data from AbbVie Inc. Annual Reports
| Ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | AbbVie Inc.'s net fixed asset turnover improved from 2015 to 2016 and from 2016 to 2017. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | AbbVie Inc.'s total asset turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders' equity. | AbbVie Inc.'s equity turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017. |
Net Fixed Asset Turnover
AbbVie Inc., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| | Net revenues | |||||
| | Property and equipment, net | |||||
| Ratio | ||||||
| | Net fixed asset turnover1 | |||||
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors | ||||||
| Abbott Laboratories | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Celgene Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | ||||||
Source: Based on data from AbbVie Inc. Annual Reports
2017 Calculations
1 Net fixed asset turnover = Net revenues ÷ Property and equipment, net
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | AbbVie Inc.'s net fixed asset turnover improved from 2015 to 2016 and from 2016 to 2017. |
Total Asset Turnover
AbbVie Inc., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| | Net revenues | |||||
| | Total assets | |||||
| Ratio | ||||||
| | Total asset turnover1 | |||||
| Benchmarks | ||||||
| Total Asset Turnover, Competitors | ||||||
| Abbott Laboratories | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Celgene Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Total Asset Turnover, Industry | ||||||
| Health Care | ||||||
Source: Based on data from AbbVie Inc. Annual Reports
2017 Calculations
1 Total asset turnover = Net revenues ÷ Total assets
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | AbbVie Inc.'s total asset turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017. |
Equity Turnover
AbbVie Inc., equity turnover calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| | Net revenues | |||||
| | Stockholders' equity | |||||
| Ratio | ||||||
| | Equity turnover1 | |||||
| Benchmarks | ||||||
| Equity Turnover, Competitors | ||||||
| Abbott Laboratories | ||||||
| Allergan PLC | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Celgene Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Equity Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| Equity Turnover, Industry | ||||||
| Health Care | ||||||
Source: Based on data from AbbVie Inc. Annual Reports
2017 Calculations
1 Equity turnover = Net revenues ÷ Stockholders' equity
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders' equity. | AbbVie Inc.'s equity turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017. |
